ATE410147T1 - Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd - Google Patents

Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Info

Publication number
ATE410147T1
ATE410147T1 AT03704789T AT03704789T ATE410147T1 AT E410147 T1 ATE410147 T1 AT E410147T1 AT 03704789 T AT03704789 T AT 03704789T AT 03704789 T AT03704789 T AT 03704789T AT E410147 T1 ATE410147 T1 AT E410147T1
Authority
AT
Austria
Prior art keywords
glycosamin
glycans
copd
heparin
respiratory diseases
Prior art date
Application number
AT03704789T
Other languages
English (en)
Inventor
Janis Kay Shute
Mary Patricia Carroll
Conway Joy H Dr
Peter Morey Hockey
Original Assignee
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27739233&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE410147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0203830A external-priority patent/GB0203830D0/en
Priority claimed from GB0203773A external-priority patent/GB0203773D0/en
Priority claimed from GB0211414A external-priority patent/GB0211414D0/en
Priority claimed from GB0224330A external-priority patent/GB0224330D0/en
Application filed by Univ Southampton filed Critical Univ Southampton
Application granted granted Critical
Publication of ATE410147T1 publication Critical patent/ATE410147T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/12—Mucolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
AT03704789T 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd ATE410147T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0203830A GB0203830D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0203773A GB0203773D0 (en) 2002-02-18 2002-02-18 Improving drug delivery to the respiratory tract
GB0211414A GB0211414D0 (en) 2002-05-17 2002-05-17 Treatment of respiratory disorders
GB0224330A GB0224330D0 (en) 2002-10-18 2002-10-18 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
ATE410147T1 true ATE410147T1 (de) 2008-10-15

Family

ID=27739233

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03704789T ATE410147T1 (de) 2002-02-18 2003-02-14 Verwendung von glykosaminglykanen wie z.b. heparin zur behandlung von atemerkrankungen wie copd

Country Status (10)

Country Link
EP (1) EP1511466B2 (de)
AT (1) ATE410147T1 (de)
AU (1) AU2003207317A1 (de)
CA (1) CA2516318C (de)
DE (1) DE60323973D1 (de)
DK (1) DK1511466T4 (de)
ES (1) ES2315479T5 (de)
HK (1) HK1074582A1 (de)
PT (1) PT1511466E (de)
WO (1) WO2003068187A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523479A (ja) 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
WO2005032483A2 (en) 2003-10-01 2005-04-14 Momenta Pharmaceuticals, Inc. Polysaccharides for pulmonary delivery of active agents
TW201306847A (zh) * 2010-11-30 2013-02-16 Vectura Ltd 組成物及用途
CA2830069C (en) 2011-03-20 2019-11-12 The University Of British Columbia Therapeutic agent for emphysema and copd
GB201611639D0 (en) 2016-07-04 2016-08-17 Ockham Biotech Ltd Delivery device and formulation
WO2019139479A1 (en) 2018-01-11 2019-07-18 Rob Janssen Compositions and methods for the treatment of lung emphysema and other forms of copd
IT202100021602A1 (it) * 2021-08-09 2023-02-09 Sofar Spa Composizione in forma di polvere secca per inalazione per uso in un metodo di trattamento di un’infiammazione e/o di uno stress ossidativo dell’apparato respiratorio causata/o da inquinamento dell’aria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668118A (en) 1992-07-24 1997-09-16 Cavalier Pharmaceuticals Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
US6235725B1 (en) * 1998-10-30 2001-05-22 Baker Norton Pharmaceuticals, Inc. Methods and compositions for the prevention of tolerance to medications
JP2004523479A (ja) * 2000-10-18 2004-08-05 マサチューセッツ　インスティテュート　オブ　テクノロジー 多糖の肺送達に関する方法および産物

Also Published As

Publication number Publication date
CA2516318A1 (en) 2003-08-21
WO2003068187A1 (en) 2003-08-21
CA2516318C (en) 2011-07-19
DK1511466T3 (da) 2009-02-16
AU2003207317A1 (en) 2003-09-04
DE60323973D1 (de) 2008-11-20
DK1511466T4 (en) 2015-03-30
EP1511466B2 (de) 2015-02-25
PT1511466E (pt) 2009-01-16
ES2315479T5 (es) 2015-07-01
ES2315479T3 (es) 2009-04-01
HK1074582A1 (en) 2005-11-18
EP1511466A1 (de) 2005-03-09
EP1511466B1 (de) 2008-10-08

Similar Documents

Publication Publication Date Title
RS20050361A (en) Novel medicament for the treatment of chronic obstructive pulmonary diseases
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
BRPI0407454A (pt) Pirazóis e métodos de preparar e usar os mesmos
HK1074582A1 (en) Use of glycosaminoglycans such as e.g. heparin for the treatment of respiratory disorders such as copd
EA200501771A1 (ru) Лиганды каннабиноидных рецепторов и их применения
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
SE0200356D0 (sv) Novel use
SE9800836D0 (sv) New Compounds
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
EA200500782A1 (ru) Лечение геморрагического шока
SE0100172D0 (sv) New inhibitors against galectins
NO20052272L (no) CCR1-antagonister for behandling av blant annet demylinerene inflamasjonssykdom
NZ594814A (en) Peptide that is derived from a milk protein and has an antioxidative effect and also acts as a blood adiponectin level increase promotion and/or decrease inhibition agent
DE60204217D1 (de) Verwendung von bioglas
NO20050063L (no) 2-heteroaryl karboksamider
TNSN07263A1 (en) Substituted 4-phenyl tetrahydroisoquinolines, methods for producing them, their use as drug, and drug containing them
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
IS2613B (is) Útskipt díketópíperasín sem oxýtósínblokkar
HRP20050579B1 (hr) Nove sinergistiäśne kombinacije koje sadrže roflumilast i formoterol
ATE526967T1 (de) Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum
NO20076405L (no) Anvendelse av 24-nor-UDCA
NO975028D0 (no) Piperazinoderivater som neurokininantagonister
EA200401305A1 (ru) Аэрозольная композиция для ингаляции, содержащая соль тиотропия
DK1594500T3 (da) Behandling af bakterielle sygdomme i respirations-organerne ved lokal applikation af fluorkinoloner
ATE444754T1 (de) Verwendung von tyrosinkinase-inhibitoren zur behandlung inflammatorischer prozesse

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1511466

Country of ref document: EP